Company: LHI
Filing Date: 2025-09-29
Form Type: F-1/A
Source: 0001213900-25-092499
Chunk: 33

Company: Living Homeopathy International Ltd.
Filing Date: 2025-09-29
Form: F-1/A
Chunk 33
---
 on this and all of our other products, whether
or not accurate. For example, the Hong Kong Department of Health issued a press release on February 27, 2023 on a case of silver poisoning
involving a senior female customer who allegedly had a history of consuming Living Colloidal, and reminds the public of not consuming
products containing colloidal silver. Our sales of LIVING Colloidal Silver were subject to our quality control procedure, comprising
conducting certain sample testing at Hong Kong STC. See “Business – Quality Control” on page 82 of this prospectus
for further details. We immediately terminated the sales of LIVING Colloidal Silver for human use. If any human consumption of LIVING
Colloidal Silver results in silver poisoning or other harmful side effects, consumers may bring legal actions against us for damages
and regulators may bring investigations or other proceedings against us which may result in our exposure to monetary and non-monetary
penalties. If so, our reputation, business growth, financial condition and results of operations will be materially and adversely affected.
Even if we are found not at fault in these legal actions or proceedings, we will have to put in substantial financial resources and managerial
attention to deal with these legal actions and proceedings, which otherwise can be applied toward our business development. As of the
date of this prospectus, we are not aware of any complaints, claims, regulator inquiries or legal proceeding relating to Living Colloidal
Silver, which, however, if occurs, will adversely affect our business, financial condition and results of operations. Any negative publicity
on us or any of our products could have a material adverse effect on our reputation and the sales of our products, which could further
materially and adversely affect our business, financial condition and results of operations.

Our business is heavily regulated and our industry may be subject to increasingly tightened regulatory requirements and scrutiny in the main markets where we operate and the new markets we will sell our products, which could potentially adversely affect our business growth, financial condition and results of operations.

As of the date of this prospectus, our primary
operations are based in Hong Kong. Our business is heavily regulated in Hong Kong and must comply with applicable laws and regulations,
including the need to obtain certain licenses and permits. For example, we are required to comply with the Food Safety Ordinance (Chapter
612 of the Laws of Hong Kong) and be registered as a food importer/distributor under the Food Safety to be able to import health supplements